胃肠间质瘤肝转移的规范化治疗

Standard treatment for liver metastases with gastrointestinal stromal tumors

胃肠间质瘤(GIST)肝转移可发生在各个风险级别和各个时期,并且严重影响病人的生存期。GIST中肝转移发生率约为15.9%,其治疗一直以来是外科领域亟待解决的问题。GIST仍以外科治疗为主,手术完整切除肿瘤和术后服用伊马替尼可改善病人预后,提高存活率。其手术方式的选择更多取决于肿瘤的部位和大小。外科治疗联合酪氨酸激酶抑制剂(TKI)治疗是GIST肝转移病人的有效方法,明显延长GIST肝转移病人的生存时间、提高生存质量。TKI联合外科治疗是GIST肝转移的最优策略。

Gastrointestinal stromal tumor （GIST） with liver metastases could occur at each risk grade/pathological staging, and seriously affect the survival rate of patients. The rate of liver metastasis from GIST is 15.9%. The treatment for GIST has been an urgent problem in the surgical field. Surgical procedures were important to the patients with GIST. Patients with GIST performed complete tumor resection and taking imatinib postoperatively could have good prognosis. The choice of the surgery ways depends more on the location andsize of tumors. Surgical therapy combined with tyrosine kinase inhibitors （TKI） may be an effective method, and increase the overall survival and improve the quality of survival for patients with liver metastasis significantly. TKI combined surgical treatment is the optimal strategy for GIST with liver metastasis.